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Viruses have evolved mechanisms of MHCI inhibition in order to evade recognition by cyto-
toxic CD8+ T cells (CTLs), which is well-illustrated by our prior studies on cowpox virus
(CPXV) that encodes potent MHCI inhibitors. Deletion of CPXV viral MHCI inhibitors
markedly attenuated in vivo infection due to effects on CTL effector function, not priming.
However, the CTL response to CPXV in C57BL/6 mice is dominated by a single peptide anti-
gen presented by H-2Kb. Here we evaluated the effect of viral MHCI inhibition on immunodo-
minant (IDE) and subdominant epitopes (SDE) as this has not been thoroughly examined.
We found that cross-priming, but not cross-dressing, is the main mechanism driving IDE
and SDE CTL responses following CPXV infection. Secretion of the immunodominant anti-
gen was not required for immunodominance. Instead, immunodominance was caused by
CTL interference, known as immunodomination. Both immunodomination and cross-priming
of SDEs were not affected by MHCI inhibition. SDE-specific CTLs were also capable of
exerting immunodomination during primary and secondary responses, which was in part
dependent on antigen abundance. Furthermore, CTL responses directed solely against
SDEs protected against lethal CPXV infection, but only in the absence of the CPXV MHCI
inhibitors. Thus, both SDE and IDE responses can contribute to protective immunity against
poxviruses, implying that these principles apply to poxvirus-based vaccines.
Author summary
The use of vaccinia virus (VACV) to eradicate smallpox is the arguably the most successful
demonstration of vaccination. The VACV vaccine also provides cross-protection against
related zoonotic orthopoxviruses, including monkey poxvirus (MXPV) and CPXV, which
circulate between various animal hosts and humans. Interestingly, Edward Jenner first
demonstrated the concept of vaccination against smallpox in the late 1700s using CPXV.
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He also made the curious observation that CPXV vaccination did not always protect
against recurrent exposure to CPXV. Jenner’s observations may be explained by the ability
for CPXV to evade antiviral CD8+ T cell immune responses. To evade CD8+ T cells,
CPXV inhibits MHCI antigen presentation, which is required to prime CD8+ T cells.
Importantly, CPXV is the only orthopoxvirus that inhibits MHCI and thus provides a
unique opportunity to investigate the effects of viral MHCI inhibition on CD8+ T cell
priming. Here, we examine the factors that contribute to priming of CPXV-specific CD8+
T cells and show that viral MHCI inhibition does not affect CD8+ T cell priming, but
prior CPXV immunization does inhibit priming during subsequent exposure to CPXV.
The effects of pre-existing poxvirus immunity are therefore important to consider if pox-
virus-based vaccines against various diseases are to be widely used.
Introduction
Strategies to leverage strong cytotoxic CD8+ T cells (CTL) responses to viral infections are of
particular interest as CTLs play essential roles in controlling viral infections [1–5]. Before gain-
ing effector functions, virus-specific CTL precursors must be primed by antigen presenting
cells (APCs) that present pathogen-derived epitopes via major histocompatibility complex
class I (MHCI) molecules on the cell surface. If the APC is infected and directly presents
endogenously produced antigens, this is known as direct presentation. Alternatively, unin-
fected APCs may process and cross-present exogenous antigens from infected cells. Cross-pre-
sentation is mediated primarily by Batf3-dependent CD103+/CD8α+ dendritic cells (DCs) [6–
8], which we refer to as BATF3+ DCs. Peptide-loaded MHCI molecules from infected cells
may also be liberated by cell lysis or secreted in exosomes and then transferred onto cross-pre-
senting APCs. When uninfected APCs acquire preformed peptide-MHCI complexes in this
manner, they are termed cross-dressed and can drive expansion of CD8+ T cells [9–11]. Induc-
tion of CD8+ T cell responses by cross-dressing was previously demonstrated in studies using
adoptive transfer of T cell receptor (TCR) transgenic (Tg) T cells [9–11] and also requires
BATF3+ DCs [11]. However, the relative contribution of these processes to non-TCR Tg CTL
responses against viral antigens is largely unknown.
Upon recognizing cognate antigen on APCs, naïve CTLs are activated to undergo clonal
expansion and traffic to the site of ongoing viral infection. There, virus-specific CTLs mediate
host resistance by recognizing infected cells via surface MHCI molecules displaying processed
viral antigens. Specific T cell recognition activates direct killing of infected cells and produc-
tion of interferon-gamma (IFN-γ) and other cytokines that may have indirect effects. In the
later stages of the response, a proportion of CTLs become long-lived memory CD8+ T cells
that can provide rapid protection during secondary responses to the viral pathogens.
Many viruses display mechanisms that may contribute to evading CTL responses, such as
inhibiting MHCI antigen presentation. The effects and mechanisms of MHCI inhibition on
CTL responses have been well demonstrated in vitro with herpesviruses [12]. For instance,
downregulation of MHCI by murine cytomegalovirus (MCMV) prevented MCMV-specific
CTLs from killing infected cells, whereas cells infected with an MCMV mutant lacking the viral
MHCI inhibitors were lysed by CTLs [13]. However, the in vivo relevance of viral MHCI inhibi-
tion in general was previously unclear since herpesvirus-mediated MHCI inhibition had few
effects on in vivo CTL responses in murine and nonhuman primate infection models [14–16].
On the other hand, studies of cowpox virus (CPXV) by our lab and others indicated that
CPXV, uniquely among the orthopoxviruses, mediated mouse and human MHCI inhibition
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by two open reading frames (ORFs), CPXV012 and CPXV203 [4,17,18]. CPXV203 retains
MHCI molecules in the ER and CPXV012 inhibits peptide loading on MHCI molecules; when
combined, these two evasion mechanisms allows CPXV to evade CTL responses. The deletion
of intact CPXV012 and CPXV203 from the CPXV genome attenuated viral pathogenesis in
vivo [4,5]. Furthermore, this attenuation was dependent on the anti-CPXV CTL response
since depleting CD8+ T cells restored the virulence of the Δ12Δ203 CPXV mutant, similar to
wild type (WT) CPXV. Thus, these studies of CPXV established the in vivo importance of viral
MHCI inhibition and its effects on antiviral CTL responses.
Interestingly, the virus-specific CTL response to CPXV in C57BL/6 mice is dominated by a
single antigen (B8), displaying the immunological phenomenon known as immunodomi-
nance, that can impede the development of efficacious vaccines [19]. In theory, removing the
IDE(s) may circumvent immunity. However, for some viruses, subdominant epitopes (SDEs)
may compensate and then dominate the immune response [20,21]. Such findings revealed that
responses against an IDE(s) suppress immune responses to SDEs, which is a related yet distinct
phenomenon coined immunodomination. CD8+ T cell immunodomination also occurs dur-
ing secondary responses whereby memory CD8+ T cells can suppress naïve CD8+ T cell
responses [22]. CD8+ T cell immunodomination is likely a mechanism that contributes to the
immunodominance of the B8 antigen in CPXV infections [23], but has not been studied in the
context of MHCI inhibition.
B8R is a highly conserved gene among orthopoxviruses and encodes the secreted soluble B8
protein that binds IFN-γ with broad species-specificity. B8 from ectromelia virus (ECTV) is a
strong inhibitor of human, bovine, rat, and murine IFN-γ [24], but VACV and CPXV B8 does
not neutralize murine IFN-γ [25]. These differences have been attributed to host-specificity. While
the natural host of ECTV is not known, experimentally it is restricted to murine hosts, whereas
VACV has a broad host-tropism with an unknown natural reservoir [26]. The natural reservoirs
of CPXV are wild-rodent species, but CPXV also has broad host-tropism [27,28]. Despite these
differences, B8 is the most dominant antigen identified in mice with the H-2Kb MHCI allele, and
the B8 CD8+ T cell epitope sequence (TSYKFESV) is 100% conserved between ECTV, VACV,
CPXV, and other orthopoxviruses [29]. However, it is not clear if B8 is an immunodominant anti-
gen because it is a secreted soluble protein that may be efficiently cross-presented.
Previously, we showed that CPXV infection of Batf3-/- mice that selectively lack the main
cross-presenting DC subsets (CD103+/CD8α+ DCs) [30] display reduced priming of B819-26-
specific CD8+ T cells during CPXV infection [5], suggesting that cross-presentation is a major
pathway used to induce CTLs. However, since Batf3–/–mice also lack the capability of cross-
dressing, it is also possible that cross-dressing is the main pathway to induce CPXV-specific
CTLs. Moreover, it remained unclear whether other CPXV antigens (i.e., SDEs) are efficiently
presented by BATF3+ DCs because CPXV B819-26 immunodominates the primary CTL
response [5]. Finally, due to the above limitations, it is not known if these processes could be
affected by viral MHCI inhibition.
Here we studied if transmembrane anchoring of B8 affects its immunodominance, the role
of MHCI inhibition in the generation of virus-specific CTLs to SDEs and for the first time, the
relevance of cross-dressing in the induction of endogenous antiviral CTL responses.
Results
Secretion of the immunodominant antigen is not a determinant for
immunodominance
The immunodominant CPXV B8 antigen is a secreted soluble protein [24], suggesting that its
immunodominance may be due to its property as a secreted molecule, as shown for other
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antigens [31,32]. If this were true, we expect that altering the protein targeting of B8 so that it
is no longer secreted from infected cells will affect the acquisition and availability of B8 for
APCs, which in turn would affect priming of B819-26-specific CD8
+ T cells and its immunodo-
minance. To test these hypotheses and detect subcellular location of B8, we produced a CPXV
mutant expressing B8 fused to mCherry (B8mC) and another mutant (B8TMmC) expressing
B8-mCherry fusion protein with a transmembrane domain (TMD) (Fig 1A).
We performed subcellular fractionation of infected HeLa cells and analyzed the cytoplasmic
extract, membrane extract, and supernatant by Western blot to determine the subcellular loca-
tion of the B8 variants and if they were secreted. The B8 variants were mainly detected in the
membrane extract of both B8TMmC- and B8mC-infected cells, indicating that the infected
cells successfully expressed both B8 variants (Fig 1B). We note that the membrane fraction
may contain proteins found within the mitochondria and endoplasmic reticulum, but not
nuclear proteins, such that the secreted B8 variant detected in the membrane fraction is likely
due to proteins localized within the ER and in transit through the secretory pathway. We also
detected higher levels of the non-secreted B8 variant in the membrane fraction in comparison
to the secreted variant, which is likely due to an accumulation of membrane-associated B8
within B8TMmC-infected cells. Most importantly, the B8 variant was detected in the superna-
tant of cells infected with B8mC, but not in the supernatant of cells infected with B8TMmC,
demonstrating that the B8 variant remains cell-associated in cells infected with B8TMmC (Fig
1B). However, anchoring the B8 antigen did not negatively affect priming of B819-26-specific
CD8+ T cells and B819-26 maintained the highest position in the immunodominance hierarchy,
as shown in mice infected intranasally (i.n.) with B8TMmC or B8mC (Fig 1C and 1D). These
data show that secretion of the B8 antigen is not required for priming of B819-26-specific CD8
+
T cells or immunodominance during CPXV infection.
We also performed kinetic analyses of B819-26-specific CD8
+ T cells by staining with H-2Kb
tetramers loaded with B819-26 peptide and found that priming by cell-associated B8 resulted in
greater expansion of B819-26-specific CD8
+ T cells (Fig 1E). These results are consistent with
previous findings that cell-associated antigens are cross-presented better than soluble antigens
[33,34]. When we infected Batf3-/- mice with B8TMmC or B8TM, we found that priming of
B819-26 -specific CD8
+ T cells was significantly reduced in Batf3-/- mice in comparison to B6
mice (Fig 1F), indicating that the introduced B8 mutations did not alter the dependence on
cross-presentation (or cross-dressing) in the induction of B819-26-specific CTL precursors.
Since priming against the non-secreted B8 protein is still dependent on cross-presenting (or
cross-dressed) BATF3+ DCs, it is likely that antigens used for conventional cross-presentation
by BATF3+ DCs are acquired from infected apoptotic/necrotic donor cells or that BATF3+
DCs are cross-dressed with peptide-loaded MHCI molecules.
Cross-presentation, but not cross-dressing of APCs, drives CTL responses
during CPXV infection
While we previously reported that priming of CD8+ T cell responses to CPXV is dependent on
cross-presenting BATF3+ DCs, others reported that direct priming is the main mechanism to
induce CTL responses with VACV infection [35,36]. To directly compare these findings, we
assessed the CTL response after systemic infection with WT CPXV, Δ12Δ203 (from here on
referred to as ΔMHCIi) CPXV, or VACV in B6 and Batf3-deficient mice. At 8 days post-infec-
tion (dpi), the frequency of splenic CD8+ T cells that produced IFN-γ in ex vivo stimulations
with ΔMHCIi-infected DC2.4 cells was significantly reduced in WT CPXV- and ΔMHCIi-
infected Batf3-/- mice (Fig 2A) in comparison to infected B6 mice, confirming the importance
of cross-presentation (or cross-dressing) in inducing CPXV-specific CTLs, as we showed
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earlier [5]. Conversely, at 6 or 8 dpi, ex vivo stimulation with a set of 5 VACV/CPXV peptides
(Fig 2B) or VACV-infected DC2.4 (Fig 2A) revealed no significant difference in the VACV-
specific response between infected B6 and Batf3-/- mice. These results are consistent with the
findings that ablation of XCR1-expressing (CD103+/CD8α+) DCs does not completely abolish
priming of CD8+ T cells during VACV infection [37]. Thus, the in vivo responses to two highly
related orthopoxviruses display distinct requirements for direct presentation (VACV) versus
cross-presentation/cross-dressing (CPXV).
Fig 1. Secretion of the immunodominant antigen is not required for immunodominance. (A) Schematic representation of the B8-mCherry
fusion proteins; the location of the signal peptide, GGSGGS linker, TMD, and mCherry are depicted. (B) B8TMmC is not secreted. HeLa cells
were infected at an MOI of 5 with B8TMmC or B8mC. Cells and supernatant were harvested at 4 hpi for subcellular fractionation and mCherry and
EGFR expression was determined by western blot; equal loading and transfer of samples was confirmed with ponceau S red (P-Red) staining.
CE = cytoplasmic extract; ME = membrane extract; SN = supernatant. Data are representative of two independent experiments. (C, D) Comparable
CTL priming by B8TMmC and B8mC. CD8+ T cell responses in the spleen of B6 (n = 5) i.n. infected with 5 x 103 pfu (C) and 1.5 x 104 pfu (D)
B8TMmC or B8mC were determined by ex vivo restimulation with CPXV peptides and ICS at 8 dpi. Data are representative of two independent
experiments. (E) Cell-associated antigen is cross-presented more efficiently than soluble antigen. B8-specific CD8+ T cell responses in the spleen of
B6 (n = 5) i.n. infected with 1.5 x 105 pfu B8TMmC or B8mC were determined by tetramer staining at 8, 9, and 10 dpi. Data are representative of two
independent experiments. (F) CD8+ T cell responses require BATF3+ DCs. B6 and Batf3-/- mice (n = 7–10) were i.n. infected with 5 x 103 pfu
B8TMmC or B8mC and the B8-specific CD8+ T cell responses in the spleen were determined at 6 dpi. n = 3 mock-infected mice. Data are the
combined results of three independent experiments.
https://doi.org/10.1371/journal.ppat.1006883.g001
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Given that priming of CPXV-specific CTL precursors and cross-dressing of APCs in other
settings were both shown to require BATF3+ DCs [11], we sought to determine if cross-dress-
ing could account for the source of antigen being presented to CD8+ T cells in CPXV infection.
To do so, we transferred B6 bone marrow (BM) into lethally irradiated Batf3-/--F1 (Batf3-/--B6
x Batf3-/--BALB/c) mice (Fig 3A). In B6!Batf3-/--F1 chimeras, donor B6-derived (Batf3-de-
pendent) APCs only express H-2b MHCI molecules and should cross-prime CTL responses
against H2b-restricted epitopes (Fig 3A). However, priming by H-2d-restricted epitopes would
occur only if the H2b APCs in these chimeric mice were cross-dressed with preformed pep-
tide-loaded H-2d class I molecules from the host parenchymal cells, which express both H-2b
and H-2d class I molecules. We also produced BALB/c!Batf3-/--F1 chimeras, to analyze the
converse situation. The reconstituted mice were infected by i.n. administration with WT
CPXV and CTL responses were determined against the immunodominant H-2Kb-restricted
B819-26 and the H-2L
d-restricted F226-34 epitopes. As expected, we detected a B819-26 response
in B6!Batf3-/--F1 mice that was of similar magnitude to non-chimeric WT-F1 (B6 x BALB/c)
infected mice (Fig 3B). We also detected a small B819-26-specific response in BALB/c!Batf3-/-
-F1, but the frequency of B819-26-specific CD8
+ T cells was significantly lower (~12-fold) than
in B6!Batf3-/--F1 and WT-F1 mice. A small, yet detectable response to F226-34 was also dete-
cted in the lungs of B6!Batf3-/--F1-infected mice, but it was ~3 fold and ~8 fold lower in
comparison to WT-F1- and BALB/c!Batf3-/--F1-infected mice respectively. Thus, these data
suggest cross-dressing contributes minimally to priming against these peptide determinants.
It is possible that cross-dressing by H-2Kb- and H-2Ld-restricted epitopes other than B819-26
and F226-34, respectively, occurred in infected chimeric mice, so we also performed ex vivo stim-
ulations with ΔMHCIi-infected DC2.4 (H-2b) and P815 (H-2d) cells as these cells present a
broad array of naturally derived CPXV peptides (Fig 3B). The frequency of IFN-γ+ CD8+ T
cells upon stimulation with ΔMHCIi-infected DC2.4 cells was significantly lower in BALB/
c!Batf3-/--F1 mice in comparison to B6!Batf3-/--F1 and WT-F1 mice. Similarly, the frequency
of IFN-γ+ CD8+ T cells upon stimulation with ΔMHCIi-infected P815 cells was significantly
lower in B6!Batf3-/--F1 mice in comparison to BALB/c!Batf3-/--F1 and ~10 fold lower in
comparison WT-F1 mice. The frequency of CD8
+ T cells that responded to ΔMHCIi-infected
P815 cells was also significantly lower in WT-F1 in comparison to BALB/c!Batf3-/--F1. This
was also seen in F226-34 responses (Fig 3B). These findings may be due to the additional epitope
Fig 2. Cross-priming induces CTL responses during CPXV infection. (A) BATF3+ DCs cross-prime CPXV-specific
CTL precursors. B6 or Batf3-/- mice (n = 6) were infected i.p. with 1 x 105 pfu WT CPXV, ΔMHCIi, or VACV-WR, and
CD8+ T cell responses were measured by ex vivo restimulation with infected DC2.4 cells and ICS at 8 dpi. The data are
the combined results of three independent experiments. (B) Induction of VACV-specific CTLs is not dependent
BATF3+ DCs. B6 or Batf3-/- mice (n = 6–7) were infected i.p. with 1 x 105 pfu VACV-WR and CD8+ T cell responses in
the spleen were measured at 6 dpi. The data are the combined results of two independent experiments.
https://doi.org/10.1371/journal.ppat.1006883.g002
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diversity from H-2b as well as H-2d expression in WT-F1, which may compromise responses to
H-2d-restricted epitopes during the primary response. Regardless, these results suggest that
Fig 3. Conventional cross-priming, but not cross-dressing, is the main mechanism driving CTL responses during
CPXV infection. (A) Schematic of bone marrow chimera cross-dressing experiment. B) CTLs are not activated by
cross-dressed APCs. Batf3-/--F1 mice (n = 5–6) were depleted of NK cells, lethally irradiated 2 days after NK cell
depletion, and reconstituted with 1 x 107 T cell depleted bone marrow cells from B6 or BALB/c mice. 8 weeks later,
chimeric mice were infected i.n. with 5 x 103 pfu WT CPXV and CD8+ T cell responses in the lungs were determined
by ICS at 8 dpi. (C) Memory CTLs are not activated by cross-dressed APCs. Chimeric mice (n = 3–5) previously
infected for 25 days were boosted with 5 x 104 pfu WT CPXV and CD8+ T cell responses in the lungs were determined
by ICS at 8 days after boost. The data are the combined results of three independent experiments.
https://doi.org/10.1371/journal.ppat.1006883.g003
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cross-dressing from non-hematopoietic cells does not generate a vigorous response during pri-
mary CPXV responses.
We next assessed whether cross-dressing plays a role during secondary responses to CPXV
infection since cross-dressed APCs are capable of stimulating memory CD8+ T cells [9]. How-
ever, the secondary CPXV response in the B6!Batf3-/--F1 and BALB/c!Batf3-/--F1 mice were
similar to what was observed in the primary CPXV response (Fig 3C). Thus, cross-dressing
from non-hematopoietic cells also plays a minor role in activating endogenous memory CD8+
T cells following CPXV infection.
To test if cross-dressed MHCI could be contributed by the hematopoietic compart-
ment, we reconstituted lethally irradiated Batf3-/--F1 mice with a 1:1 mixture of BALB/c-
Thy1.1 and Batf3-/--F1 BM (S1A Fig). In these mice, cross-presentation should only be
carried out by the donor BALB/c-Thy1.1-derived APCs (H-2d). In contrast, cells that are
of the donor Batf3-/--F1 (H-2b x H-2d) origin will lack BATF3+ DCs and should not carry
out cross-presentation, but may serve as a source of cross-dressing peptide-MHCI com-
plexes. We systemically infected BALB/c-Thy1.1 + Batf3-/--F1!Batf3-/--F1 mice with WT
CPXV and found that the H-2d-restricted response was successfully reconstituted, whereas
the H-2b-restricted response was significantly lower than the response in WT-F1 mice and
was comparable to Batf3-/--F1!Batf3-/--F1 control mice (S1B Fig). These data indicate that
APCs cross-dressed from other hematopoietic cells does not efficiently prime CD8+ T cell
responses in the setting of effective viral MHCI inhibition.
Taken together, these data suggest that antigens are predominantly cross-presented by
BATF3+ DCs during CPXV infection and that cross-dressing plays a minor role, if at all.
Cross-presentation of SDEs in the absence of the IDE induces a robust
CD8+ T cell response that is not affected by viral MHCI inhibition,
revealing immunodomination
Insufficient cross-presentation of SDEs may explain the subdominance of other CPXV anti-
gens. To test if cross-presentation of CPXV SDEs alone is capable of inducing a strong CTL
response, we mutated the B819-26 epitope anchor residues required for binding to H-2K
b pep-
tide-binding groove, postulating that this will prevent the B819-26 epitope from being presented
by H-2Kb. According to the peptide-binding motif of H-2Kb, the B819-26 epitope contains a
primary anchor residue (phenylalanine at position P5) and an auxiliary anchor residue (tyro-
sine at position P3) [38]. To determine whether mutating the primary anchor residue is suffi-
cient to eliminate binding to H-2Kb or if both anchor residues should be mutated, peptide-
binding assays were performed using the transporter associated with antigen processing 2
(TAP2)-deficient RMA-S cell line in which addition of peptides capable of binding H-2Kb sta-
bilize its expression on the cell surface [39]. Alanine substitution of the primary anchor residue
significantly reduced binding of the B819-26 epitope peptide to H-2K
b as compared to WT B8,
but binding could be increased with increasing concentrations of peptide (S2A Fig). However,
alanine substitutions of the primary and auxiliary anchor residues completely abrogated bind-
ing of the B819-26 epitope peptide to H-2K
b, even at higher peptide concentrations. Based on
these findings, we introduced both substitutions into the WT and the ΔMHCIi CPXV
genomes. The CPXV B819-26 epitope mutants B8Y3AF5A (referred to as ΔB819-26) and a B8R
deletion mutant (ΔB8R) that we generated did not exhibit defects in viral replication in vitro
(S2B Fig). Surprisingly, they also did not show attenuated virulence in vivo, as measured by
weight loss or lethality, as compared to WT CPXV (S2C Fig).
There was no detectable B819-26 response in ΔB819-26- or ΔMHCIiΔB819-26-infected mice
(Fig 4A and 4B, S3A and S3B Fig). However, infections with ΔB819-26 or ΔMHCIi-ΔB819-26
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generated a robust SDE response. In contrast, as we previously reported [5], a large proportion
of the CPXV-specific CTL response was directed against B819-26 in the lungs of WT- and
ΔMHCIi-infected mice. Additionally, there were no significant differences between the overall
CTL responses against WT, ΔB819-26, ΔMHCIi, and ΔMHCIiΔB819-26 (Fig 4A and 4B), despite
the loss of the B819-26-specific response. Therefore, the CTL response was completely compen-
sated by SDEs in the absence of a B819-26 response.
It was possible that the B819-26 epitope mutation allows CPXV to replicate to higher titers in
the lungs of infected mice resulting in higher antigen loads, which could explain the observed
Fig 4. Cryptic subdominant epitopes can compensate for the loss of the CPXV immunodominant epitope-specific CTL response, revealing
immunodomination. CTL immunodomination occurs during primary responses against CPXV. (A and B) B6 mice (n = 11–13) were infected i.n
with 5 x 103 pfu of WT, ΔB819-26, ΔMHCIi, or ΔMHCIiΔB819-26 and were sacrificed at 8dpi. CD8
+ T cells in the lungs were restimulated with B819-26
peptide or DC2.4 cells infected with ΔMHCIi or ΔMHCIiΔB819-26. The legend to B indicates the viruses used for infections and the X-axis indicates
the stimuli used for ex vivo restimulation and ICS. Data are the combined results of five independent experiments. (C) WT and mutant viral strains
replicate to similar titers. Viral titers in the lungs of infected B6 mice were determined at 8 dpi by plaque assay. (D and E) Comparable CTL
responses against all viral strains tested. B6 mice (n = 6) were infected by i.p. and splenic CD8+ T cells were restimulated with peptides (D) or with
DC2.4 cells infected with ΔMHCIi or ΔMHCIiΔB819-26 (E). Data are the combined results of four independent experiments.
https://doi.org/10.1371/journal.ppat.1006883.g004
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compensation. However, the B819-26 epitope mutations did not result in significantly increased
viral titers in infected mice (Fig 4C), suggesting that the compensation is unlikely due to
increased antigen loads.
Immunodomination and priming by SDEs were also not affected by CPXV-mediated MHCI
inhibition since there were no significant difference in the SDE response against ΔB819-26 and
ΔMHCIiΔB819-26, as measured by stimulation with ΔMHCIi- (used to estimate total response)
or ΔMHCIiΔB819-26- (used to estimate total SDE response) infected DC2.4 cells (Fig 4A and 4B).
Additionally, there was no significant difference in the frequency of CD8+ T cells that exhibited
an effector T cell phenotype in infected mice (S3C and S3D Fig). Considering that the route of
infection can alter antigen levels and immunodominance [23], we infected mice by intraperito-
neal (i.p.) injections. Compensation by SDEs was also observed during systemic infection (Fig
4D and 4E), suggesting that compensation was not dependent on antigen levels or the route of
infection. However, CTL responses against the panel of subdominant epitopes we tested were
not significantly increased in the absence of B819-26, suggesting that other unidentified or cryptic
subdominant epitopes compensated the CTL response. Interestingly, the response against A4288-
96 was significantly reduced in the absence of the B819-26-specific response (Fig 4D), suggesting
that SDEs were up-ranked in the dominance hierarchy and were now themselves eliciting
immunodomination. Furthermore, we found that priming of SDE-specific CD8+ T cells was also
dependent on BATF3+ DCs (S3E Fig). These data suggest that the IDE-specific CTL response
suppresses cross-priming of SDE-specific CD8+ T cells during primary CPXV infections, indi-
cating immunodomination, but this process was not affected by viral MHCI inhibition.
SDE-specific CD8+ T cell are effective at immunodomination during
primary and secondary CPXV infection
Memory CD8+ T cells also have a capacity for immunodomination and can inhibit naïve
CD8+ T cell responses [22]. However, this is not the case for VACV since prior priming with
individual SDEs does not alter the immunodominance hierarchy following VACV boost in
SDE-primed mice [40]. Considering that the priming mechanisms are different during VACV
and CPXV infection (Fig 2A), we tested whether CPXV-specific memory CD8+ T cells can
exert immunodomination. We primed mice with WT CPXV, boosted the mice with a low or
high dose of ΔB819-26 at 25 dpi, and assessed the CD8
+ T cell response in the lungs and spleens
8 days after boosting (Fig 5A). In this group, B819-26-specific memory CD8
+ T cells should be
present pre- and post-boost, but will not undergo expansion following boost with ΔB819-26. As
expected, we detected B819-26-specific CD8
+ T cells in the lungs and spleens of WT CPXV-
primed mice after boosting with ΔB819-26 (Fig 5B and 5C) and before boosting (Fig 5D). Addi-
tionally, we found that WT and ΔMHCIi infection resulted in a similar relative abundance of
B819-26-specific CD8
+ T cells with a memory phenotype (CD44+CD62L+KLRG1-CD127+) at
25 dpi, suggesting that viral MHCI inhibition does not affect memory T cell development (S4
Fig). In a separate group, mice were primed with SDEs by ΔB819-26 infection and boosted with
WT CPXV. In this group, we would expect mice to mount a naïve B819-26 response after boost-
ing with WT CPXV only in the absence of memory CD8+ T cell immunodomination. How-
ever, the naïve B819-26 response was significantly inhibited following boost with both a low and
high dose of WT CPXV, suggesting that the SDE-specific memory CD8+ T cells immunodomi-
nate naïve CD8+ T cells. Alternatively, neutralizing antibodies may have reduced the antigen
levels and therefore limited the naïve B819-26 response following boost with CPXV.
To assess the potential role of host-protective antibodies, we repeated the above experi-
ments, but this time we depleted CD8+ T cells prior to challenging mice with CPXV (S5A and
S5B Fig) and then monitored the mice for survival. CPXV-immunized mice that received
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CD8-depleting or isotype control antibodies survived, whereas naïve mice succumbed to the
challenge (S5C Fig). Although this was somewhat expected because CPXV evades CTLs, these
results suggest that host-protective antibodies may contribute to protection in the absence of
CD8+ T cells during secondary exposure to CPXV. We thus repeated the prime and boost
experiments and examined immunodomination in μmT mice, which lack mature B cells.
Because CPXV evades CTLs in vivo and μmT mice should not mount a protective antibody
response, it is likely that μmT mice are highly susceptible to WT CPXV infection. To avoid
this issue, we infected μmT mice with ΔMHCIi CPXV strains as CTLs can effectively control
these viruses in WT mice. We primed μmT mice by skin scarification (s.s.) infection, which
resembles human immunizations with VACV. We then boosted the mice at 25 dpi by i.n.
administration, and subsequently assessed the CD8+ T cell response 7 days after boost. Mice
primed with ΔMHCIi resulted in expansion of a B819-26-specific CD8
+ T cells following i.n.
boost with ΔMHCIi (Fig 5E). Mice primed with ΔMHCIiΔB819-26 also mounted a detectable
response against B819-26 following i.n. boost with ΔMHCIi, yet this response was significantly
reduced by ~9-fold in comparison to mice immunized with ΔMHCIi. Therefore, memory
CD8+ T cell immunodomination still occurred in the absence of neutralizing antibodies and
viral MHCI inhibition, suggesting that immunodomination may be due to T cell interference.
Because memory CD8+ T cells are present at higher frequencies than naïve antigen-specific
CD8+ T cells, it is likely that memory CD8+ T cells have a competitive advantage in accessing
APC resources [41–43]. For instance, downregulation of MHCI on infected cells may limit the
level of antigen presented during CPXV infection, thereby contributing to T cell cross-competi-
tion for peptide-MHCI complexes in the secondary response. Indeed, T cell cross-competition
for peptide-MHCI complexes during secondary responses has been demonstrated using a heter-
ologous prime-boost strategy [44], but to our knowledge this has only been directly tested
between memory and naïve T cells specific for IDEs. To test if SDE-specific memory CD8+ T
cells can cross-compete with naïve B819-26-specific CD8+ T cells, we performed a competition
experiment in which we primed mice with ΔB819-26, adoptively transferred peptide-pulsed BM-
derived dendritic cells (BMDCs) at 25 dpi, and then assessed the CD8+ T cells responses 6 days
after transfer. Transfer of B819-26-pulsed BMDCs into ΔB819-26 -primed mice resulted in a
robust B819-26 response (Fig 5F). Likewise, transfer of K36-15-pulsed BMDCs resulted in moder-
ate expansion of K36-15-specific memory CD8
+ T cells. However, when BMDCs that were
pulsed with B819-26 and K36-15 at the same time were transferred the B819-26 response was inhib-
ited, further supporting the findings that memory CD8+ T cells immunodominate naïve CD8+
T cells. Conversely, B819-26-specific CD8
+ T cells dominated the response when BMDCs pulsed
with B819-26 and K3L6-15 at the same time were transferred into naïve mice (Fig 5G). If immuno-
domination is an effect of cross-competition, then providing BMDCs that exclusively present
K36-15 and BMDCs that exclusively present B819-26 alone should overcome the effects of immu-
nodomination. When B819-26-pulsed BMDCs were mixed with K36-15-pulsed BMDCs (pulsed
separately) and transferred into ΔB819-26-primed mice, the B819-26 response was significantly
Fig 5. CPXV subdominant epitope-specific memory CTLs immunodominate responses by naïve CD8+ T cells. (A) Schematic of i.n. prime/
boost experiment. (B and C) Immunodomination of naïve CD8+ T cells. B6 mice (n = 5–6) were primed i.n. with 5 x 103 pfu, i.n. boosted at 25
dpi with 5 x 103 pfu (B) or 5 x 104 pfu (C), and sacrificed 8 days after boosting. CD8+ T cell responses in the lungs (top) and spleens (bottom)
were determined by ICS. Data are the combined results from two independent experiments. (D) Generation of memory CD8+ T cells. i.n.
primed mice were sacrificed at 25 dpi and memory CD8+ T cells were measured in the spleen by ICS. (E) Antibody-independent memory CTL
immunodomination. μmT mice were primed by s.s. with 1 x 105 and i.n. boosted with 1 x 105 pfu at 25 dpi. CD8+ T cell responses in the spleens
were determined 7 days after boost. Data are the combined results from two independent experiments. (F) Memory CTLs cross-compete for
peptide-MHCI complexes on APCs. Peptide-pulsed BMDCs were adoptively transferred by tail vein injection into ΔB819-26-primed B6 mice
(n = 4) and CD8+ T cell responses in the spleen were evaluated by ICS 6 days after transfer. (G) Naïve CD8+ T cells do not cross-compete for
peptide-MHCI complexes on APCs. Peptide-pulsed BMDCs were transferred into naïve B6 mice and CD8+ T cell responses were evaluated by
ICS as in the experimental setup of F. Data are representative of two independent experiments.
https://doi.org/10.1371/journal.ppat.1006883.g005
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greater than in mice that received BMDCs pulsed with B819-26 and K3L6-15 at the same time,
suggesting that cross-competition plays a role in memory CD8+ T cell immunodomination.
Interestingly, the B819-26 response in mice that received the 1:1 mixture of K3L6-15-pulsed
and B819-26-pulsed BMDCs was significantly lower than in mice that only received B819-26-
pulsed BMDCs. Therefore, the partial rescue of the B819-26 response when the epitopes were
presented on different APCs suggest that additional factors contribute to immunodomination
during secondary responses. In contrast to the secondary response, separating the K36-15 and
B819-26 epitopes during primary responses had no effect on immunodomination of B819-26-
specific CD8+ T cells (Fig 5G), suggesting that cross-competition for peptide-MHCI complexes
contributes to immunodomination mainly during secondary responses.
Having demonstrated that SDE-specific memory CD8+ T cells have a capacity for immuno-
domination, we asked if SDE-specific CD8+ T cells could exhibit immunodomination during
primary responses. We reasoned that modulating the immunodominant and subdominant
antigen levels may allow SDE-specific CD8+ T cells to immunodominate. To test this, we per-
formed co-infection experiments in which the level of WT and ΔB819-26 input were varied
while maintaining the overall viral dose. We first synchronized the infections to limit the varia-
tion in the dose by infecting freshly harvested splenocytes with either WT or ΔB819-26 sepa-
rately. We then mixed WT- and ΔB819-26-infected splenocytes at a ratio of 1:0, 10:1, 1:10, or
0:1, inoculated mice intravenously (i.v.) with a total of 1 x 105 infected cells, and assessed the
CTL response at 7 dpi (Fig 6A). A graded B819-26 response was observed with the concurrent
increase of ΔB819-26 input and decrease of WT input (Fig 6B), while the overall response as
determined by stimulation with ΔMHCIi-infected DC2.4 cells remained roughly equal (Fig
6C). These data suggest that SDE-specific CTLs are capable of immunodominating the pri-
mary response when the relative abundance of subdominant antigens is increased, even in the
presence of the IDE. To confirm that the graded response was not simply due to reduced WT
input, we repeated the co-infection experiment using mixtures of WT- and mock-infected
splenocytes. Injecting the varying mixtures of WT- and mock-infected splenocytes did not
result in a gradation of the B819-26 response (Fig 6B), suggesting that the observed graded B819-
26 response was dependent on the subdominant antigen levels.
SDE-primed CD8+ T cells control lethal CPXV infection in the absence of
the CPXV MHCI inhibitors
Thus far, our results indicate that CPXV-mediated MHCI inhibition does not affect priming of
CD8+ T cells by SDEs. However, we wondered whether SDE-specific CTL responses could pro-
vide protection against CPXV infection in vivo. To examine the physiological relevance of SDEs
in protecting against CPXV infection, we performed adoptive transfer experiments with CTLs
primed with ΔB819-26 or MCMV as a control for antigen specificity (Fig 7A). Mice that received
primed CTLs were then challenged by i.n. administration with a lethal dose of ΔB819-26 or
ΔMHCIiΔB819-26. The majority of mice that received MCMV-primed CTLs died following infec-
tion with ΔB819-26 or ΔMHCIiΔB819-26 (Fig 7B and 7C). All mice that received ΔB819-26-primed
CTLs also died after challenge with ΔB819-26, whereas all mice challenged with ΔMHCIiΔB819-26
survived. Therefore, CTLs primed by SDEs are capable of recognizing and controlling CPXV only
in the absence of CPXV-mediated MHCI inhibition, which is consistent with our previous find-
ings regarding WT CPXV exposure that is dominated by the B819-26 response [4,5].
Discussion
Here we demonstrate that the secretion of an immunodominant CPXV antigen does not affect
immunodominance or cross-priming by the IDE. Intriguingly, we found that the IDE and
Immunodomination and viral MHCI inhibition
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006883 February 14, 2018 13 / 24
SDEs are differentially presented by APCs during infection with CPXV and VACV, despite
being closely related genetically. We also show that CD8+ T cell immunodomination is not
affected by viral MHCI inhibition and can be elicited by SDEs during primary and secondary
responses against CPXV infection. Additionally, we show that SDEs alone are entirely capable
of generating protective CTL responses, which is dependent on cross-priming by BATF3+
DCs.
Cross-priming of CD8+ T cells is important for inducing antiviral CTL responses, especially
in settings where direct-presentation is not possible (e.g., APCs are not susceptible to infec-
tion) or is evaded (e.g., impairing maturation of infected-APCs or inhibiting MHCI presenta-
tion). Consistent with this notion, herein we showed that the induction of antiviral CTL
responses is dependent on cross-presentation in the presence of CPXV-mediated MHCI inhi-
bition. Priming of CD8+ T cell in the absence of viral MHCI inhibition during CPXV infection
was also dependent on cross-presenting BATF3+ DCs, albeit to a less extent. While we have
not ruled out the possibility that ΔMHCIi-infected BATF3+ DCs prime CTL precursors by
direct presentation, CPXV-infected DCs have reduced expression of costimulatory molecules
involved in T cell activation [45,46], suggesting that direct-presentation may be limited even in
Fig 6. CPXV subdominant epitopes gain dominance when the relative abundance of subdominant antigens is
increased during primary responses. (A) Schematic of co-infection experiment. Splenocytes were harvested from B6
mice and infected at an MOI of 5 with WT CPXV and ΔB819-26 separately or mock-infected. At 1 hpi, infected cells were
mixed at different ratios and a total of 1 x 105 infected cells were administered into naïve B6 mice (n = 5–6) by tail vein
injection. (B and C) A role for antigen levels in CTL immunodomination. Mice were sacrificed at 7 dpi and splenic CD8+
T cells were restimulated with B8 peptide (B) or with DC2.4 cells infected with ΔMHCIi (C). Data are the combined
results from two independent experiments.
https://doi.org/10.1371/journal.ppat.1006883.g006
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the absence of CPXV012 and CPXV203. Nonetheless, there are clearly factors other than
MHCI inhibition that skew priming of T cells towards cross-priming and further study of
CPXV ORFs in the context of ΔMHCIi provides an excellent opportunity to investigate such
factors. In this study, we provide evidence that cross-priming is the main mechanism driving
CPXV-specific CTL responses.
Our studies also indicate that cross-dressing plays no significant role in the T cell response
to CPXV infections in vivo. Cross-dressing has been proposed as a mechanism by which APCs
can rapidly acquire peptide epitopes for presentation to CTL precursors, thereby eliminating
the time spent for antigen processing [9,10]. In support of this, DCs can be cross-dressed in
vitro by peptide-MHCI complexes from epithelial cells [47], which are commonly targeted by
viruses and thus may serve as a common source of preformed viral peptide-MHCI. Moreover,
peptide-MHCI from parenchymal cells cross-dressed DCs in vesicular stomatitis virus (VSV)-
infected mice and the cross-dressed DCs induced proliferation of memory CD8+ T cells, but
not naïve T cells. However, priming of naïve antigen-specific CD8+ T cells by cross-dressed
DCs can occur, as demonstrated using DNA vaccination and transfer of adenovirus infected
DCs [10,11]. In contrast to these studies, we found that cross-dressing does not efficiently
prime or drive expansion of endogenous antigen-specific naïve and memory CD8+ T cells dur-
ing CPXV infection.
While previous reports on cross-dressing provide compelling evidence that cross-dressing
occurs in vivo, the transfer of TCR tg T cells in these studies may have resulted in non-physio-
logical induction of CD8+ T cells by cross-dressed DCs. Additionally, cross-dressing in these
experimental settings may have been promoted due to a potential generation of supraphysiolo-
gical levels of peptide-MHCI by DNA vaccination or by transfer of adenovirus infected DCs.
These factors may explain the difference between previous studies and our results using CPXV
infection. Because CPXV encodes an extensive arsenal of immunomodulatory proteins, the
Fig 7. Subdominant epitope-specific CTL responses protect against CPXV infection. (A) Schematic of adoptive transfer experiment. B6 mice
were primed with ΔB819-26 or MCMV by subcutaneous (s.c.) or i.p. routes, respectively. At 7 dpi, splenic CD8
+ T cells were isolated by positive
selection and adoptively transferred into naive B6 mice (n = 11–13) by tail vein injection. After ~1 day, mice were infected by i.n. inoculation
with ΔB819-26 or ΔMHCIiΔB819-26 and monitored for survival (B) and weight loss (C). Data are the combined results from two independent
experiments.
https://doi.org/10.1371/journal.ppat.1006883.g007
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possibility that CPXV directly or indirectly inhibits cross-dressing may also explain these con-
flicting results. For example, downregulation of MHCI cell surface expression by CPXV012
and CPXV203 may prevent transfer of peptide-loaded MHCI molecules by trogocytosis, a pro-
cess in which intercellular exchange of intact membranes occurs during the formation of an
immunological synapse [48–51]. If trogocytosis is required for cross-dressing of APCs in vivo,
as been demonstrated in vitro [9], then cross-dressing dependent T cell responses are expected
to be abrogated during CPXV infection. Ultimately, our results suggest that antigens are
acquired from necrotic/apoptotic bodies or secreted viral proteins found in the extracellular
milieu and are then predominantly cross-presented during CPXV infection.
Cross-presentation of peptide epitopes may also be influenced by the nature of the antigens
and can affect the extent of CD8+ T cell immunodominance [52–54]. For instance, the secreted
immunodominant antigens of M. tuberculosis are likely processed through the cross-presenta-
tion pathway [55,56] and eliminating bacterial secretion prevents priming of IDE-specific CD8+
T cells during M. tuberculosis infection [31]. Priming of naïve CD8+ T cells against cell-associ-
ated subdominant SV40 large tumor antigen (T Ag) epitope V is also dependent on cross-pre-
sentation, but the response against the V epitope is limited because it is inefficiently cross-
presented relative to the T Ag IDE [54]. Our findings suggest that cross-presented CPXV IDEs
can be derived from cell-associated antigen since ablating B8 secretion did not negatively affect
cross-priming dependent induction of B819-26-specific CD8
+ T cells. Moreover, cell-associated
B8 elicited a greater B819-26-specific CD8
+ T cell response in comparison to secreted soluble B8,
which is consistent with the preferential in vivo cross-presentation previously reported for cell-
associated antigens [33,34]. However, the underlying mechanisms of immunodominance are
complex and are often context dependent as we found that secretion of CPXV B8 is not
required for immunodominance and that cross-presentation of CPXV SDEs in the absence of
the immunodominant B819-26 epitope stimulated a robust CTL response. The fact that the CTL
response to SDEs compensated for the absence of B819-26 suggests that the SDE response is sup-
pressed by the B819-26 response, supporting the concept of immunodomination.
In many cases immunodomination occurs as a consequence of T cell competition for limit-
ing APC resources [41,43,57,58]. For instance, competition for peptide-MHCI complexes on
APCs during primary CTL responses can occur as a result of antigen abundance [59]. In sup-
port of this, we showed that concurrently increasing subdominant antigen levels and reducing
immunodominant antigen levels allow SDEs to gain dominance during the primary response
to CPXV infection. Similarly, modulating the antigen abundance through different methods
during influenza A virus and VACV infection has been shown to influence immunodomina-
tion [23,60]. In certain models, immunodomination can be overcome when APCs present dif-
ferent epitopes separately [42,51,58], indicating that CD8+ T cells of different specificities can
cross-compete for peptide-MHCI complexes on APCs. This has been convincingly demon-
strated in models where immunodomination occurs when APCs co-present model antigen
epitopes. However, epitope co-presentation by APCs does not always influence immunodomi-
nation, as we have shown here for primary responses, and the role of cross-competition in
inducing antiviral CTL responses is controversial [61].
We found that cross-competition for peptide-MHCI complexes is relevant and that im-
munodomination occurs during secondary responses as a consequence. Alternatively, the
suppressed B819-26 response in our cross-competition experiments may have resulted from
K36-15-specific memory CD8
+ T cells killing the BMDCs that were pulsed with B819-26 and
K3L6-15 at the same time. Nevertheless, we observed partial rescue of the B819-26 response
when the epitopes were separated on BMDCs. This partial rescue may be due to peptide
exchange between BMDCs that were pulsed separately and adoptively transferred as a mix,
which would subsequently result in epitope co-presentation and K36-15-specific memory
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CD8+ T cell immunodomination. However, additional factors that we did not test such as
cross-competition for growth factors, antigen-specific T cell precursor frequencies, or TCR
avidity [62] likely contribute to the memory T cell immunodomination as well.
Remarkably, immunodomination during the secondary response against CPXV was
exerted by SDE-specific memory CD8+ T cell. The capacity for SDE-specific memory CD8+ T
cells to inhibit the response to an IDE has been shown with influenza virus [22], but prior
priming with SDE peptides did not result in memory CD8+ T cell immunodomination using
VACV, as shown by Wang et al [40]. Here in our study, memory CD8+ T cell immunodomina-
tion was clearly evident when SDE-primed mice were challenged with WT CPXV, whereby
the naïve B819-26-specific CD8+ T cell response was suppressed. Moreover, memory CD8+ T
cell immunodomination was not affected by MHCI inhibition. However, mice were primed by
CPXV infection (in this study) as opposed to individual SDE peptides (as done by Wang et al).
These experimental differences suggest that the priming stimulus and the breadth of the pri-
mary response influences immunodomination during secondary responses against poxviruses.
Taken together, our findings highlight the need to consider the effects of pre-existing
immunity on the outcome of secondary responses and vaccinations. An advantage to using
VACV-based vaccines is that in addition to providing protection against heterologous patho-
gens, the native vector epitopes (both IDEs and SDEs) can provide cross-protection against
related orthopoxviruses, as supported by our findings here and previous reports [63–66]. How-
ever, as a consequence of pre-existing immunity, memory CD8+ T cell immunodomination
may limit the target antigen response following immunization with VACV-based vaccines, in
turn resulting in non-efficacious vaccinations. For example, native VACV epitopes can mask
responses against target antigens expressed by VACV vaccine vectors [19]. Nevertheless, our
results support the ongoing evaluation for poxviruses as promising vaccine vectors, and stress
the necessity to develop novel vaccination strategies.
Materials and methods
Cell lines, mice and viruses
Cell lines HeLa, Vero, and P815 were obtained from the American Type Culture Collection
(ATCC). DC2.4 cells were a kind gift from Dr. Kenneth Rock, University of Massachusetts
Medical School. HeLa, Vero, DC2.4, and P815 cells were cultured respectively in Dulbecco’s
Modified Eagle Medium (DMEM), Minimum Essential Medium (MEM) or RPMI supple-
mented with 10% FBS (Mediatech), 100 U/ml penicillin, 100 g/ml streptomycin, 1mM sodium
pyruvate, and non-essential amino acids (Gibco). VACV-WR was obtained from the ATCC.
MCMV Smith strain was a gift from Dr. Herbert Virgin, Washington University. CPXV BAC
pBR mini-F construct was kindly provided by Dr. Karsten Tischer, Free University of Berlin.
Mutant viruses were generated by en passant mutagenesis [67] using primers listed in S1
Table. Gene fragments were synthesized (Integrated DNA Technologies) and assembled using
Gibson Assembly (New England BioLabs) for cloning of the B8-mCherry fusion contructs (S2
Table). Infectious BAC-derived viruses (S3 Table) were reconstituted using a slightly modified
method previously described by Xu et al [68]. In brief, ~8x105 Vero cells seeded in 6-well plates
were infected with fowlpox virus (FWPV) at an MOI of 1. Transfection of FWPV-infected
Vero cells was carried out 1 hour post-infection (hpi) with 4 μg of BAC DNA and 5 μL of Lipo-
fectamine 2000 transfection reagent (ThermoFisher Scientific) according to the manufactur-
er’s instruction. Serial dilutions of reconstituted infectious virus were passaged up to four
times on Vero cells in order to remove the mini-F vector sequence. Wells harbouring single
GFP-negative plaque were isolated and used for preparing virus stocks as previously described
[17]. C57BL/6Ncr mice were purchased from the National Cancer Institute.
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B6.129S2-Ighmtm1Cgn/J mice were purchased from the Jackson Laboratory. Batf3-/- mice
crossed to the C57BL/6 and BALB/c background were kindly provided by Dr. Kenneth Mur-
phy, Washington University. Growth curves were performed on Vero cells. Supernatant and
cells were harvested at 12, 24, 28, and 72 hpi and viral titers were determined by plaque assay
using Vero cells.
Peptide binding assay
TAP2-deficient RMA-S (H-2b) cells were cultured overnight at 28˚C in 5% CO2 to accumulate
peptide-receptive MHCI molecules at the cell surface. Peptides were then added at various
concentrations and the cells were transferred to 37˚C. After 6 h of incubation at 37˚C, cells
were harvested and washed twice in PBS. H-2Kb cell surface expression was then measured by
flow cytometry.
Western blot
1 x 106 HeLa cells were infected at a MOI of 5. Cells and supernant were collected at 4 hpi and
were lysed on ice for 5 min in RIPA lysis buffer supplemented with 1x Halt protease and phos-
phatase inhibitor cocktail. Cells were further processed for subcellular fractionation using a
Subcellular Protein Fractionation Kit (ThermoFisher). Samples were mixed with Laemmli
sample buffer (Bio-Rad), incubated at 95˚C for 5 minutes, separated by SDS-PAGE, and trans-
ferred to PVDF membranes. Immunoblotting was performed using rabbit polyclonal anti-
mCherry and rabbit monoclonal anti-EGFR (Abcam) followed by horseradish peroxidase
(HRP)-conjugated goat anti-rabbit IgG (Cell Signalling).
Generation of bone marrow chimeras
6 weeks of age Batf3-/--F1 (H2bxH2d) mice were depleted of NK cells by i.p. administration of
100 μg of PK136 antibody. Two days later, the mice were lethally irradiated with 950 rads and
were reconstituted with 1x107 T cell depleted C57BL/6, BALB/c, or a 1:1 mixture of BALB/c-
Thy1.1 and Batf3-/--F1 BM cells. BM chimeras were treated with antibiotics for 4 weeks and
were allowed to reconstitute for 8 weeks before use.
Generation of bone marrow-derived DCs and immunization
BMDCs were generated by culturing BM cells in the presence of 20 ng/mL GM-CSF and IL-4
(PeproTech) for 8 days, as previously described [69]. LPS (150ng/nL) was then added and the
cells were allowed to mature overnight. The cells were then pulsed with peptide (1g/mL, 45
min). Cells were washed extensively in PBS and a total of 2.5 x 105 DCs was injected i.v. into
recipient mice.
Mouse infection and CD8+ T cell adoptive transfer
Mice were age- and sex-matched for each experiment and used at 8–10 weeks of age. Mice
were infected as previously described for i.n. and s.s. infections [5]. For s.s. infections, fur was
trimmed with clippers, then a thin layer of Vaseline was applied over the trimmed region and
the remaining fur was shaved over with a double-edge razor blade one day before infection.
Mice infected by i.p. or s.c. administration were injected with a volume of 100μL or 200μL of
virus inoculum per mouse, respectively. For co-infection experiments, splenocytes isolated
from B6 mice were infected at an MOI of 5, harvested 1 hpi, and washed three times with PBS.
1 x 105 infected cells in 200 μL of PBS were transferred intravenously into naïve B6 mice. For
the CPXV SDE protection experiment, CD8+ T cells from splenocytes of B6 mice that had
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been infected 7 days earlier with WT CPXV or MCMV were isolated by positive selection
using anti CD8a MicroBeads (Miltenyi Biotec). 3 x 106 CD8+ T cells were transferred intrave-
nously into naïve B6 mice. Mice were infected approximately 24 h after transfer.
Flow cytometry, IFN-γ production assays, and antibodies
Single-cell suspensions from the lungs and spleens were prepared at the indicated days
post-infection as previously described [5]. 1x106 cells were seeded in 96-well plates and were
re-stimulated with peptides or with 1x105 DC2.4 cells that had been infected for 4 h with
ΔMHCI-i or ΔMHCI-iΔB8 CPXV (MOI 5). Cells were incubated at 37˚C, 5% CO2. After 1 h at
37˚C, GolgiPlug (BD Biosciences) was added to each well. Three hours later, cells were stained
on ice with Fixable Viability Dye eFlour 506 (eBioscience) before staining of cell surfaces for
the indicated surface markers. Cells were then fixed/permeabilized and stained for IFN-γ.
Background levels were determined using cells from uninfected mice, which usually ranged
between 0.01–0.05%, and were subtracted from the values presented. For intracellular staining
of GzmB and tetramer staining, cells were stained ex vivo without stimulation and without
incubation with GolgiPlug. H-2Kb-TSYKFESV tetramers were produced in the Immunomoni-
toring Laboratory within the Center for Human Immunology and Immunotherapy Programs
(Washington University). The following monoclonal antibodies were obtained from Thermo-
Fisher, BD Biosciences or eBioscience: H-2Kb (AF6-88.5), CD3 (145-2C11), CD8α (53–6.7),
CD8β (eBioH35-17.2), CD4 (RM4-5), CD44 (IM7), CD62L (MEL-14), GzmB (GB12), KLRG1
(2F1), CD127 (A7R34) and IFN-γ (XMG1.2).
Statistics
The data are shown as mean ± SEM and were analysed with an unpaired Student t test or one-
way ANOVA followed by Tukey posttest comparison using Prism GraphPad software, aster-
isks indicate statistical significance and the p values are denoted as p<0.05, p<0.01,
p<0.001.
Ethics statement
Mouse studies were approved by the Animal Studies Committee at Washington University,
protocol # A-3381-01, and adhere to the Institutional Animal Care and Use Committee
guidelines.
Supporting information
S1 Fig. Cross-dressing by hematopoietic cells does not induce CTL responses during
CPXV infection. (A) Schematic of bone marrow chimera cross-dressing experiment.
(B) Hematopoietic cells do not contribute to CTL-priming via cross-dressing of APCs. Lethally
irradiated Batf3-/--F1 mice (n = 8) reconstituted with a 1:1 mixture of BALB/c-Thy1.1 and
Batf3-/--F1 bone marrow cells were infected i.p. with 1 x 105 pfu WT CPXV and CD8+ T cell
responses in the spleen were assessed as in the experimental setup in Fig 3. n = 4 WT-F1
CPXV-infected mice. The data are the combined results of three independent experiments.
(TIF)
S2 Fig. Mutating the CPXV immunodominant CD8+ T cell epitope anchor residues alters
peptide binding affinity to MHCI H-2Kb, but does not affect CPXV replication and viru-
lence. Peptide binding assays were performed using RMA-S cells. (A) Peptide anchor residues
are critical for H-2Kb binding. Cell surface staining of H-2Kb after incubation with peptide
(black) or without peptide (red) are shown; isotype control staining is shown in grey. Data are
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representative of three independent experiments. (B) B8 mutations do not affect viral kinetics
in vitro. Vero cells were infected at an MOI of 0.01 for multi-step growth curves. Data are the
combined results of three independent experiments performed in duplicates. (C) B8 mutations
do not affect viral pathogenesis in vivo. B6 mice (n = 5–9) were infected i.n. with 4 x 104 pfu of
the indicated viruses and monitored for survival and weight loss.
(TIF)
S3 Fig. Cross-priming of cryptic subdominant epitopes can compensate for the loss of the
CPXV immunodominant epitope-specific CTL response. Peptide anchor residues are criti-
cal for inducing B819-26-specific CTL responses. (A and B) B6 mice (n = 10) were infected i.n
with 5 x 103 pfu WT, ΔB819-26, ΔMHCIi, or ΔMHCIiΔB819-26 and were sacrificed at 8dpi. The
B819-26-specific CTL response in the spleen was evaluated by tetramer staining. Data are the
combined results from two independent experiments. (C and D) Comparable CTL responses
against all viral strains. B6 mice (n = 5) were infected and sacrificed at 8 dpi as in experimental
setup of A and B. Cell surface expression of CD62L, CD44 and intracellular GzmB was deter-
mined for CD8+ T cells in the lungs. Data are representative of three independent experiments.
(E) BATF3+ DCs cross-prime SDE-specific CTL precursors. B6 or Batf3-/- mice (n = 7) were
infected i.p. with 1 x 105 pfu ΔB819-26 and CD8
+ T cell responses in the spleen were measured
by ex vivo restimulation with ΔMHCIiΔB819-26-infected DC2.4 cells. ICS was performed at 8
dpi. Data are the combined results from two independent experiments.
(TIF)
S4 Fig. Viral MHCI inhibition does not affect the generation of memory CD8+ T cells. (A
and B) Generation of memory CD8+ T cells following CPXV infection. B6 mice (n = 7) were
primed i.n. with 5 x 103 pfu WT or ΔMHCIi and were sacrificed at 25 dpi. Cell surface expres-
sion of memory T cell markers (CD62L, CD44, KLRG1, and CD127) was determined for
TET+CD8+ T cells in the spleen. Data are the combined results from two independent experi-
ments.
(TIF)
S5 Fig. CPXV-immunized mice survive lethal challenge in the absence of memory CD8+ T
cells. (A) Schematic of immunization and challenge experiment. B6 mice (n = 6–7) were
primed i.n. with 5 x 103 pfu of CPXV and lethally challenged at 25 dpi. Anti-CD8α or isotype
control antibodies were administered at the indicated times. (B) Complete depletion of CD8+
T cells. The efficiency of antibody-mediated CD8 depletion was determined one day after the
first administration of antibodies. (C) CPXV immunized mice generate protective antibody
responses. Challenged mice were monitored for survival and weight loss.
(TIF)
S1 Table. Primer sequences.
(TIF)
S2 Table. Synthesized gene fragments.
(TIF)
S3 Table. Viruses used in this study.
(TIF)
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